Ksarelto (Xarelto) - is an anticoagulant of direct action. Available in the form of tablets, film-coated with an active substance content of 10, 15 and 20 milligrams. The active substance - rivaroxaban micronized.

Mode of action and pharmacodynamics

 The mechanism of action by Ksarelto instruction is to direct inhibition of factor Xa
 According to the instructions, Ksarelto inhibits factor Xa and also has anticoagulant effect.

The mechanism of action by Ksarelto instruction is to direct inhibition of factor Xa. Rivaroxaban has high selectivity and has high bioavailability (80-100 percent) during ingestion. Activation by external and internal way of coagulation factor X to form factor Xa plays the most important role in the coagulation cascade.


Rivaroxaban is rapidly absorbed - the maximum concentration in blood is reached after two to four hours after eating pills. After ingestion of a large part of rivaroxaban (92 to 95 percent) binds to plasma proteins, the main binding component - serum albumin.

When administered about two-thirds dose rivaroxaban metabolized and subsequently derived in equal parts with the feces and urine. The remaining third excreted unchanged via direct renal excretion, primarily due to active renal secretion.

Indications for use Ksarelto

According to the instructions, Ksarelto in the form of tablets of 10 mg is indicated for the prevention of venous thromboembolism in people who were exposed to large orthopedic surgical interventions on the nature of the lower extremities.

Tablets Ksarelto 15 and 20 mg are indicated for the prevention of systemic thromboembolism and stroke in people with non-valvular atrial fibrillation origin, as well as for the treatment of pulmonary embolism and deep vein thrombosis, for preventing recurrence of DVT and PE.

Contraindications Ksarelto

 Ksarelto produced in the form of tablets, film-coated with an active substance content of 10, 15 and 20 milligrams
 According to the instructions, Ksarelto is contraindicated in:

  • Hypersensitivity to the active substance (rivaroxaban), or any other substances which are contained in the tablets;
  • Intracranial, gastrointestinal or other bleeding;
  • Concomitant treatment with any other anticoagulants;
  • A condition in which there is a high risk of major bleeding;
  • Pregnancy and lactation;
  • Liver disease, for which there is coagulopathy;
  • The age of eighteen;
  • Severe renal failure;
  • Lactose or galactose intolerance hereditary.

Side effects when used Ksarelto

Reviews Ksarelto indicate that the use of tablets Ksarelto may be accompanied by the risk of overt or occult bleeding from any tissue or organs, which can lead to anemia, hemorrhagic nature. Also, according to reviews, Ksarelto can cause hemorrhagic complications, weakness, dizziness, paleness, shortness of breath, headache, increased limb or shock.

Dosage and application Ksarelto

Tablets Ksarelto 10 milligrams taken irrespective of meals, 15 and 20 milligrams - during meals.

After major surgery on the knee treatment duration is two weeks after major surgery on the hip joint - five weeks. The initial dose is taken six to ten hours after surgery if hemostasis achieved. The recommended dose is one tablet a day.

When skipping the dose should immediately take the pill Ksarelto and continue to take the drug on a regular basis on the following day, respectively recommendations. To compensate for the missed dose received double the dose is prohibited.

Analogs Ksarelto

Rivaroxaban is an analogue Ksarelto.